[No standalone website (unbranded, no questionnaire)] A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site

Study’s contact

Call center

+49 3528 4041 60

Email address

hoepping@abx.de

Condition

Prostate Cancer,Prostate Cancer Recurrent

Treatment type

Interventional

Investigational product

[18F]PSMA-1007

Phase

Phase 3

Sponsor

ABX advanced biochemical compounds GmbH

ClinicalTrials.gov identifier

NCT04742361

Study number

ABX-CT-303

Understanding clinical trials

Get answers to your questions about clinical trials.

About the study

This study evaluates the diagnostic performance and safety of [18F]PSMA-1007 PET/CT imaging in patients with suspected recurrence of prostate cancer after previous definitive treatment.

Who can take part?

You may be eligible to participate in the study if you meet the following criteria:

Inclusion criteria

  1. Male with original diagnosis of adenocarcinoma of the prostate with prior definitive therapy
  2. Suspicion of recurrence or persistence
  3. after radiotherapy or cryotherapy: 3 consecutive PSA rises and/or PSA rise by 2.0 ng/mL or more above nadir (ASTRO-Phoenix)
  4. after prostatectomy, PSA > 0.2 ng/mL on 2 or more determinations (recurrence), or failure of PSA to fall to undetectable levels post-prostatectomy (persistence) (American Urological Association)
  5. For patients who previously had radical prostatectomy, salvage radiotherapy is one likely treatment plan; for patients who initially underwent radiotherapy (including brachytherapy), confirmation of low volume disease is needed to define (local) treatment.
  6. Life expectancy of 6 months or more as judged by the investigator
  7. Willing and able to undergo all study procedures
  8. Informed consent in writing
Exclusion criteria

  1. Age: less than18 years
  2. Contraindications to any of the ingredients of [18F]PSMA-1007
  3. Close affiliation with the investigational site
  4. At the time of enrolment into this study, participating in another therapeutic clinical trial or has completed study participation in another therapeutic clinical trial within 5 days of enrolment into this trial
  5. Having been previously enrolled in this clinical trial
  6. Mental conditions rendering the subject incapable to understand the nature, scope, and consequences of the trial
  7. Being clinically unstable or requiring emergency treatment
  8. Patients who are unwilling to consider a biopsy if clinically recommended
  9. Patients who are unable to undergo a PET/CT scan
  10. Patients for whom systemic therapy is the most likely course regardless of PET findings.

For a full list of inclusion/exclusion criteria, please visit ClinicalTrials.gov

Study locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site